Compare Clorox Co (CLX) vs Heron Therapeutics Inc (HRTX) Price & Performance

CLX trades at $95.05, down 1.56% on the day, with technical indicators showing a bearish trend. The company reported strong Q1 2026 earnings beat with EPS of $1.64 versus $1.55 expected, though revenue trends remain flat. Recent corporate developments include a simplified operating structure announcement and CEO transition for health reasons. The stock offers a 5%+ dividend yield with recent H1-26 dividend of $1.24 payable May 2026.

CLX presents a mixed outlook with attractive dividend income but faces growth challenges. The 8.7% upside to consensus price target of $103.38 suggests moderate potential, though high P/B ratio of 41.4 and declining revenue projections for 2026 warrant caution. Key risks include execution of new operating structure and competitive pressures in consumer staples.

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.